As it’s estimated that the marketing of pharmaceutical products accounts for up to $25 billion of spending each year, there is a lot at stake for healthcare professionals everywhere. In recent times, there’s been much talk about the methodology used by pharmaceutical companies and the tactics they utilise as their sales force members contact and try and convince professionals. Some people feel that this industry requires more regulation and some factors have tried to influence the U.S. Congress to look more deeply into the business. With these dynamics in the background, the pharmaceutical company must take a highly focused and professional approach to the very way that it acts and how it reaches the people responsible for buying products and generating revenues enabling it to survive in the first place.
Certain countries around the World have been quick to introduce legislation and restrictions governing how pharmaceutical companies may interact with professionals. Some countries such as Australia, for example, have established certain codes of conduct, setting standards for ethical marketing and insisting that member organisations comply with the requirements.
Pharmaceuticals sales executives will spend a lot of time involved in what is known as “detailing,” by visiting front line professionals and explaining how the product might work, giving market suggestions, likely product availability, how it should be dosed, side effects that could be expected and other details. This will require highly polished communication skills and sales executives must be able to overcome barriers to growth over the years due to distrust or suspicion. The sales executive has a pivotal role to play in helping to give the professional supplemental educational information. Much attention must be paid to these marketing methods by the pharmaceutical company.
If additional new regulations or restrictions develop in the near future, this would put even more emphasis on the need for effective marketing by the organisation. A company should engage pharmaceutical consulting firms due to the fact that they have direct experience and can as such help to train and educate the sales force so that they do not stumble at a vital time, make mistakes or negatively interact with professionals and spoil any potential gains.
Disclosure may be called for in future, detailing hospitality provided or suggested, levels of assistance given or gifts related and a clear indication of the style and type of education imparted. As the very way that the sales executive markets the product becomes more complex, the product itself must, of course, be the subject of high levels of education and understanding in the first place.
Generally, pharmaceutical consultants will focus a great deal of their available time on striving to balance training between methods and product awareness. Staff will be trained in the essential elements of time management, and in addition to the dissemination of traditional marketing skills, any up-to-date or new legal requirements will be the subject of focus. Company chiefs should outsource these methods to pharma consulting, enabling them to focus on other areas. With ineffective marketing, reputations can be compromised and there can be other implications, including problems with regulations and authorities; consultants must steer the organisation carefully.
Alan Gillies is the CEO of L2L Consulting, a cutting-edge pharma consultancy firm which specialises in optimising productivity and performance within international companies by applying tailored organisational strategies.